12:00 AM
 | 
Sep 21, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Saphris asenapine: Additional Phase III data

Additional data from 386 patients in a double-blind Phase III trial showed that Saphris met a secondary endpoint of significantly longer time to treatment discontinuation for any reason vs. placebo (p<0.001). Data were presented at European College of Neuropsychopharmacology in Istanbul.

Schering-Plough, which...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >